US FDA grants fast track designation to DualityBio's next-generation HER3 ADC DB-1310 to treat nonsquamous non-small cell lung cancer: Shanghai Wednesday, July 23, 2025, 14:30 Hrs ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Discover the future of Canada's Oncology Market with our comprehensive "Canada Oncology Market Outlook to 2033" report. Covering key segments like Colorectal Cancer and PD-L1 tests, it includes ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

When standard cancer treatments begin to fail, especially in aggressive or advanced stages, oncologists are increasingly ...

The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 ...

AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 ...

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

UCLA Health researchers at the Jonsson Comprehensive Cancer Center have recently won a pair of grants worth in total nearly ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...